Could a rheumatoid arthritis drug ease Sjogren's symptoms?
NCT ID NCT05016297
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether baricitinib, a drug already used for rheumatoid arthritis, can help people with active Sjogren's syndrome. 87 participants were randomly assigned to receive either hydroxychloroquine alone or baricitinib plus hydroxychloroquine for 24 weeks. The goal was to see if baricitinib improves disease activity and symptoms like dryness and fatigue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
baricitinib
What this could lead to
If it works, this could point toward a new treatment option for Sjogren's syndrome, a chronic autoimmune disease causing dry eyes and mouth.
What could go wrong
This is a small, early-phase trial (phase 2) with only 87 participants. Results may not apply to all patients, and baricitinib carries risks like infections and blood clots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China